Amid Lawsuit, San Diego Stem Cell Company Pushes Back On Proposed Regulations
By David Wagner,
KPBS
| 12. 05. 2016
San Diego-based Stemgenex is asking regulators to let patients have access to stem cell treatments it calls "life-altering." But patients currently suing the company claim they were charged thousands of dollars for falsely advertised treatments that didn't improve their health.
In a press release issued last week, the La Jolla company outlined its argument against the U.S. Food and Drug Administration's proposed plans for regulating stem cell treatments. Stemgenex argues the proposed rules would treat a patient's own stem cells as a drug, subjecting stem cell therapies to a lengthy and expensive approval process.
Stemgenex's press release claims the rules, if finalized, "will delay access to stem cell therapies in the United States and cause many Americans who are struggling with degenerative disease to seek treatment outside of the county (sic)."
Jeanne Loring, a stem cell scientist at the Scripps Research Institute, spoke in favor of the proposed rules at an FDA meeting in September. Loring believes these kinds of stem cell clinics need regulation because in her opinion they are "selling something that doesn't work, for a very...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
